CFDE Data Portal | Search PIGO-AS1

	Label	Description
	PIGO-AS1 Gene (Entity type)	ENSG00000234181 - PIGO antisense RNA 1
	GSE150244 TRIM8 knockout 3 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216273 GSE216292 palbociclib 14 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE200982 PLAC8 knockout 0 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE113655 phenol 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 14 v 12 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE114883 0 V 5 ROMIDEPSIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE193993 SSTR2 knockout 4 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE149901 3 V 1 ANLOTINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE236896 GSE237665 DNMT EZH2 inhibition 1 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS

PIGO-AS1

ENSG00000234181 - PIGO antisense RNA 1

GSE150244 TRIM8 knockout 3 v 0 human dn

A Gene Set from LINCS

GSE216273 GSE216292 palbociclib 14 v 1 human dn

A Gene Set from LINCS

GSE200982 PLAC8 knockout 0 v 2 human dn

A Gene Set from LINCS

GSE113655 phenol 1 v 2 human dn

A Gene Set from LINCS

GSE111247 temozolomide LN-308 14 v 12 human dn

A Gene Set from LINCS

GSE114883 0 V 5 ROMIDEPSIN HUMAN DN

A Gene Set from LINCS

GSE193993 SSTR2 knockout 4 v 7 human dn

A Gene Set from LINCS

GSE149901 3 V 1 ANLOTINIB HUMAN DN

A Gene Set from LINCS

GSE236896 GSE237665 DNMT EZH2 inhibition 1 v 5 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.